Share on StockTwits

BioMarin Pharmaceutical (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 2,000 shares of the stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $61.20, for a total transaction of $122,400.00. Following the completion of the transaction, the chief executive officer now directly owns 229,157 shares in the company, valued at approximately $14,024,408. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

BMRN has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Monday, May 5th. They now have a $61.00 price target on the stock. Separately, analysts at Nomura reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Friday, May 2nd. They now have a $77.00 price target on the stock. Finally, analysts at Ned Davis Research upgraded shares of BioMarin Pharmaceutical from a “sell” rating to a “neutral” rating in a research note on Monday, April 21st. Nine analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $81.15.

Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) traded up 0.36% during mid-day trading on Thursday, hitting $63.33. 1,744,560 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a one year low of $53.53 and a one year high of $84.25. The stock’s 50-day moving average is $58.62 and its 200-day moving average is $68.06. The company’s market cap is $9.241 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, May 1st. The company reported ($0.01) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.44) by $0.43. The company had revenue of $151.60 million for the quarter, compared to the consensus estimate of $145.16 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. The company’s quarterly revenue was up 18.5% on a year-over-year basis. Analysts expect that BioMarin Pharmaceutical will post $-1.71 EPS for the current fiscal year.

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.